A detailed history of Allworth Financial LP transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Allworth Financial LP holds 22,580 shares of PHAT stock, worth $395,601. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,580
Previous 22,580 -0.0%
Holding current value
$395,601
Previous $239,000 2.93%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 24, 2024

BUY
$6.99 - $10.71 $20,970 - $32,130
3,000 Added 15.32%
22,580 $206,000
Q1 2023

Apr 18, 2023

BUY
$6.19 - $12.36 $14,781 - $29,515
2,388 Added 13.89%
19,580 $139,000
Q4 2022

Jan 13, 2023

BUY
$9.18 - $11.53 $25,850 - $32,468
2,816 Added 19.59%
17,192 $0
Q3 2022

Oct 18, 2022

BUY
$6.46 - $12.11 $92,868 - $174,093
14,376 New
14,376 $159,000

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $686M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.